

Application Serial No. 10/027,603
Amendment dated September 6, 2005
Reply to Office Action of June 3, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-57. (canceled)

58. (withdrawn) A method of inhibiting endothelial cell proliferation, comprising contacting said cells with an EG-VEGF antagonist in an amount effective to inhibit cell proliferation.

59-79. (canceled)

80. (currently amended) An ~~antagonist of EG-VEGF, wherein the antagonist comprises an~~ antibody or antibody fragment that specifically binds ~~a polypeptide comprising amino acid~~ residues 20-105 of SEQ ID NO:2 and inhibits EG-VEGF induced proliferation of endothelial cells.

81. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a monoclonal antibody or monoclonal antibody fragment.

82. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a chimeric antibody or chimeric antibody fragment.

83. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody is a humanized antibody or humanized antibody fragment.

84. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

85. (currently amended) The antibody or antibody fragment of claim 81, wherein the monoclonal antibody ~~or monoclonal antibody fragment~~ is produced ~~from by~~ a hybridoma cells having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

Application Serial No. 10/027,603
Amendment dated September 6, 2005
Reply to Office Action of June 3, 2005

86. (previously presented) The antibody or antibody fragment of claim 85, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.
87. (previously presented) The antibody or antibody fragment of claim 85, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
88. (canceled)
89. (previously presented) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.
90. (previously presented) The antibody or antibody fragment of claim 89, wherein the antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
- 91-92. (canceled)
93. (currently amended) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment specifically binds a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
94. (currently amended) A composition comprising the antibody or antibody fragment of claim 80 in ~~admixture~~admixture with a carrier.
95. (previously presented) The composition of claim 94, wherein the carrier is a pharmaceutically acceptable carrier.
96. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a monoclonal antibody or monoclonal antibody fragment.
97. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a chimeric antibody or chimeric antibody fragment.
98. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.

Application Serial No. 10/027,603
Amendment dated September 6, 2005
Reply to Office Action of June 3, 2005

99. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

100. (currently amended) The composition of claim 96, wherein the monoclonal antibody ~~or monoclonal antibody fragment~~ is produced from by a hybridoma cells having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

101. (previously presented) The composition of claim 100, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.

102. (previously presented) The composition of claim 100, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.

103. (previously presented) The composition of claim 94, wherein the antibody or antibody fragment inhibits EG-VEGF induced proliferation of endothelial cells.

104. (previously presented) An article of manufacture, comprising:

- (a) a container;
- (b) a label on the container; and
- (c) the composition of claim 95.

105. (canceled)

106. (new) The antibody or antibody fragment of claim 81, wherein the monoclonal antibody fragment is a fragment of a monoclonal antibody produced by a hybridoma having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

107. (new) The composition of claim 96, wherein the monoclonal antibody fragment is a fragment of a monoclonal antibody produced by a hybridoma having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

108. (new) An antagonist of EG-VEGF, wherein the antagonist comprises an antibody or antibody fragment that specifically binds a polypeptide comprising SEQ ID NO:2.